FIRST TRACKS BIOTHERAP.

First Tracks Biotherapeutics, spun off from AnaptysBio in 2026 and listed on Nasdaq since April 2026, is coming into focus with the antibody candidate ANB033. A small study showed positive signals that ANB033 can selectively influence immune signaling pathways and could alleviate both celiac disease and a chronic inflammatory disease of the esophagus. » More on finanzen.net

First Tracks Biotherapeutics presented its pipeline at the Wells Fargo Healthcare Conference, focusing on ANB033, a CD122 antibody that blocks both IL-15 and IL-2 signaling pathways and is in a Phase I–II study for celiac disease and eosinophilic esophagitis (EoE). The company cited near-term data milestones: cohort 1 (gluten challenge) in Q4 2024, cohort 2 (healing) in Q1 2025, and EoE data in H2 2025. First Tracks highlighted ANB033’s differentiating dual mechanism and subcutaneous dosing, viewing it as a potential first program to address both TH2 and CD8 pathways. Management said existing cash is expected to fund operations through Q2 2028 and plans, depending on the data, to expand into additional indications in H1 2027. » More on de.investing.com